The present invention relates to
placenta tissue-derived multipotent stem cells and
cell therapeutic agents containing the same. More specifically, to a method for producing
placenta stem cells having the following characteristics, the method comprising culturing
amnion, chorion,
decidua or
placenta tissue in a medium containing
collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into
mesoderm-,
endoderm- and
ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into
muscle cells, vascular endothelial cells, osteogenic cells,
nerve cells,
satellite cells, fat cells,
cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases,
osteoporosis,
osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of
breast tissue.